BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical & Diagnostic

Yipurun's Corina System Receives Approval in China for Treating Moderate-to-Severe Intrauterine Adhesions

Corina Intrauterine Drug-Eluting System ("Corina"), developed by Yipurun (Shanghai) Biotechnology Co., Ltd. ("YPR"), has received approval i...

August 26, 2024 | News

Finnish Biotech NADMED Secures €3.5M to Transform Vitamin B3 Testing with Groundbreaking NAD Measurement Technology

Finnish biotech company NADMED has developed the first test to measure all four bodily forms of vitamin B3, called NADs, and glutathiones directly from fre...

August 23, 2024 | News

Tackling Dengue: Insights from Leading Experts Amid Surge in Southeast Asia

In an exclusive interview with BioPharma APAC, Professor Ooi Eng Eong, a leading expert in Emerging Infectious Diseases at Duke-NUS Medical School,...

August 22, 2024 | Interview

Astellas Pharma Gains NMPA Approval for PADCEV™ in China to Treat Advanced Urothelial Cancer

Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") announced that the Center for Drug Evaluation (CDE) of C...

August 20, 2024 | News

Driving Healthcare Innovation in Asia: Rehan Saghir of ZP Therapeutics on Pioneering Drug Commercialization and Overcoming Regional Challenges

In an exclusive interview with BioPharma APAC, Rehan Saghir, Executive Vice President of ZP Therapeutics, Zuellig Pharma shares his expert insights...

August 20, 2024 | News

Vimgreen Pharmaceuticals Completes Enrollment for Phase 2 Trial of Novel A2A Receptor Antagonist in Parkinson's Disease

Vimgreen Pharmaceuticals, a science-driven pharmaceutical company focused on the modulation of adenosine signaling, announced the completion of enrollment ...

August 16, 2024 | News

Akeso’s Ivonescimab Granted Priority Review by China's NMPA for First-Line Treatment of PD-L1 Positive NSCLC

Akeso, Inc. announced that the National Center for Drug Evaluation of the State Drug Administration of the People's Republic of China (NMPA CDE) ...

August 15, 2024 | News

UAE Approves LEQEMBI® for Early Alzheimer’s Treatment, Marking a Milestone in Regional Healthcare

Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved humanized anti-so...

August 14, 2024 | News

Lynk Pharmaceuticals Reports Positive Phase 1b Results for Skin-Restricted JAK Inhibitor LNK01004 in Atopic Dermatitis Treatment

Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, announced positiv...

August 13, 2024 | News

Angiex Initiates Patient Dosing in Phase 1 Clinical Trial of AGX101, a First-in-Class TM4SF1-Directed Antibody-Drug Conjugate for Solid Cancers

Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that patient dosing has begun for t...

August 12, 2024 | News

Genova Diagnostics Launches Innovative Non-Invasive Alzheimer's Blood Test in Strategic Partnership with Neurocode

Genova Diagnostics, a global leader in clinical laboratory services, proudly announces the launch of its groundbreaking Alzheimer's Assessment, a non...

August 12, 2024 | News

Sanyou Bio and JiAnTeBo Forge Strategic Partnership to Innovate Metabolic Disease Therapies

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") and Guangdong JiAnTeBo Biotechnology Co., Ltd. (hereinafter r...

August 08, 2024 | News

Senhwa Biosciences Receives FDA Green Light for Phase I/II Trial of Silmitasertib in Pediatric Relapsed Refractory Solid Tumors

Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious disea...

August 07, 2024 | News

GSK Singapore Secures HSA Approval for Jemperli Combo Therapy in Advanced Endometrial Cancer

GSK Singapore is pleased to announce that the Singapore Health Sciences Authority (HSA) has approved a new indication for Jemperli (dostarlimab). Jemperli ...

August 07, 2024 | News

Stay Connected